Vaxart, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Vaxart, Inc. (VXRT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of -$100.00 thousand for the 12-month period ending 2014-06-30, per its 10-K filed 2015-09-11.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2015-09-11
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2012-12-31 was $2.66M, a 39.81% increase year-over-year.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2011-12-31 was $1.90M.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2014 was -$100.00K, a 109.09% decline from fiscal 2013.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2013 was $1.10M, a 62.07% decline from fiscal 2012.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2012 was $2.90M.
- Vaxart, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2011 was -$1.30M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|---|---|
| 2014-06-30 | -$100.00K 10-K · filed 2015-09-11 | ||
| 2013-06-30 | $1.10M 10-K · filed 2015-09-11 | ||
| 2012-12-31 | $2.66M 10-Q · filed 2013-02-11 | $2.95M 10-Q · filed 2013-02-11 | |
| 2012-06-30 | $2.90M 10-K · filed 2014-09-30 | ||
| 2011-12-31 | $1.90M 10-Q · filed 2013-02-11 | $2.49M 10-Q · filed 2013-02-11 | |
| 2011-06-30 | -$1.30M 10-K · filed 2013-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |